Literature DB >> 16238638

The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting.

G W Hanlon1.   

Abstract

Acinetobacter spp. have emerged in recent years as a major cause of nosocomial infections that are associated with significant morbidity and mortality. Developing resistance patterns have prompted the suggestion that we are closer to the end of the antibiotic era with Acinetobacter than with methicillin-resistant Staphylococcus aureus (J Hosp Infect58, 2004, 167).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238638     DOI: 10.1111/j.1472-765X.2005.01791.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  12 in total

1.  Mentholation triggers brand-specific shifts in the bacterial microbiota of commercial cigarette products.

Authors:  Leena Malayil; Suhana Chattopadhyay; Prachi Kulkarni; Lauren Hittle; Pamela I Clark; Emmanuel F Mongodin; Amy R Sapkota
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-24       Impact factor: 4.813

2.  Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.

Authors:  Alessia Bertini; Laurent Poirel; Sandrine Bernabeu; Daniela Fortini; Laura Villa; Patrice Nordmann; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

3.  Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.

Authors:  Laurent Poirel; Wejdene Mansour; Olfa Bouallegue; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

4.  Successful management of nosocomial ventriculitis and meningitis caused by extensively drug-resistant Acinetobacter baumannii in Austria.

Authors:  M Hoenigl; M Drescher; G Feierl; T Valentin; G Zarfel; K Seeber; R Krause; Aj Grisold
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

5.  Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation.

Authors:  Jeremy A Iwashkiw; Andrea Seper; Brent S Weber; Nichollas E Scott; Evgeny Vinogradov; Chad Stratilo; Bela Reiz; Stuart J Cordwell; Randy Whittal; Stefan Schild; Mario F Feldman
Journal:  PLoS Pathog       Date:  2012-06-07       Impact factor: 6.823

6.  Quantitative proteomic analysis of host--pathogen interactions: a study of Acinetobacter baumannii responses to host airways.

Authors:  Jose Antonio Méndez; Jesús Mateos; Alejandro Beceiro; María Lopez; María Tomás; Margarita Poza; Germán Bou
Journal:  BMC Genomics       Date:  2015-05-30       Impact factor: 3.969

7.  Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii.

Authors:  Maia Merabishvili; Dieter Vandenheuvel; Andrew M Kropinski; Jan Mast; Daniel De Vos; Gilbert Verbeken; Jean-Paul Noben; Rob Lavigne; Mario Vaneechoutte; Jean-Paul Pirnay
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

8.  Molecular survey of aminoglycoside-resistant Acinetobacter baumannii isolated from tertiary hospitals in Qazvin, Iran.

Authors:  P Rashvand; A Peymani; M Mohammadi; A A Karami; R Samimi; S Hajian; D Porasgari; N Habibollah-Pourzereshki
Journal:  New Microbes New Infect       Date:  2021-04-23

9.  Detection of Extended-Spectrum β-Lactamases among Acinetobacter Baumannii Isolated from Hospitals of Qazvin, Iran.

Authors:  Mina Zarabadi-Pour; Amir Peymani; Narges Habibollah-Pourzereshki; Mohammad Reza Sarookhani; Ali Akbar Karami; Amir Javadi
Journal:  Ethiop J Health Sci       Date:  2021-03

10.  Phenotypic and genotypic characteristics of tetracycline resistant Acinetobacter baumannii isolates from nosocomial infections at Tehran hospitals.

Authors:  Mohammad Hossein Maleki; Zamberi Sekawi; Setareh Soroush; Farid Azizi-Jalilian; Khairollah Asadollahi; Sattar Mohammadi; Mohammad Emaneini; Morovat Taherikalani
Journal:  Iran J Basic Med Sci       Date:  2014-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.